Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00854087 |
|
Recruitment Status :
Completed
First Posted : March 2, 2009
Results First Posted : June 18, 2014
Last Update Posted : May 19, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Current treatment of chronic liver disease relies upon removing the primary insult to the liver (e.g., alcohol) or treating the underlying viral infection (HBV, HCV, etc.). However, in the case of hepatitis C, a significant number of individuals will not clear the virus with current approved standard antiviral therapy, leaving them no options to manage their hepatic fibrosis, which can progress to cirrhosis and ultimately hepatocellular carcinoma (HCC).
Fuzheng Huayu has been used in numerous studies in China and has been found to have a satisfactory prophylaxis effect on the chronic liver injury and formed liver fibrosis in rats and humans. In addition, it enhances the degradation of liver fibrosis and protects hepatocytes from injury and death, manifesting as decreasing of ALT and AST, and enhancement of albumin level. In addition, preliminary studies indicate that the Fuzheng Huayu has a good safety and tolerability profile with promising efficacy.
The number of patients failing Interferon based therapy (i.e. not achieving SVR) is increasing. There are no approved standard of care treatment options for this population nor for patients who are intolerant or unwilling to receive Interferon; thus they are at higher risk for the progression of fibrosis. Moreover, there are no approved therapies to treat hepatic fibrosis, but basic research is exploring the pathophysiological mechanisms. Fuzheng Huayu is easy to administer, with a good safety and efficacy profile against fibrosis. Therefore, the investigators propose to further study the safety and efficacy profile of Fuzheng Huayu in a randomized, placebo-controlled, double blind study in Chronic Hepatitis C patients with hepatic fibrosis who have failed prior anti-HCV therapy or are intolerant or refuse Interferon based therapy.
The primary objective of this study is to establish the safety and efficacy of Fuzheng Huayu treatment in chronic hepatitis C subjects who have failed prior anti-HCV therapy or cannot receive or refused Interferon based therapy in improving liver fibrosis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Hepatitis C Infection | Drug: Fuzheng Huayu Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 118 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis |
| Study Start Date : | August 2010 |
| Actual Primary Completion Date : | April 2013 |
| Actual Study Completion Date : | August 2013 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Fuzheng Huayu
Pill with Fuzheng Huayu
|
Drug: Fuzheng Huayu
The subjects will be taking 2 tablets three times a day for 48 weeks.
Other Names:
|
|
Placebo Comparator: Placebo
Pill without Fuzheng Huayu (sugar pill)
|
Drug: Placebo
The subjects will be taking 2 tablets three times a day for 48 weeks. |
- Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. [ Time Frame: Baseline to Week 60 ]Safety will be evaluated through the changes in vital signs, physical examinations, adverse events, concomitant medication assessments as well as laboratory tests.
- Efficacy of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. [ Time Frame: Baseline to Week 48 ]
Efficacy of Fuzheng Huayu treatment was assessed through the change in liver fibrosis stage from the assessment before (pre) and after (post) study drug. The liver fibrosis staging system used was the Ishak scale. The Ishak liver fibrosis score ranges from 0 indicating no fibrosis to 6 indicating cirrhosis.
"Fibrosis improved" was defined as a lower post study drug Ishak score, by at least 1 point, from pre-study drug assessment of the liver fibrosis e.g. if a pre study drug Ishak score of 4 and then a post study drug Ishak score of 3 or lower.
"Fibrosis did not change" was defined as having the same Ishak score before and after study drug assessments e.g. if a pre study drug Ishak score of 4 and then a post study drug Ishak score of 4.
"Fibrosis worsened" was defined as a higher post study drug Ishak score, by at least 1 point, from pre-study drug assessment of the liver fibrosis e.g. if a pre study drug Ishak score of 4 and then a post study drug Ishak score of 5 or higher.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Male or female 18-70 years of age.
- Chronic hepatitis C infection based on documented history of a positive serum anti-HCV antibody test and/or detectable levels of HCV RNA ≥ 50 IU/mL.
- Failure to achieve sustained Virologic response (SVR) with previous Interferon based therapy or subjects who refuse Interferon based therapy or are intolerant to Interferon.
- All subjects enrolling in the study and all fertile or potentially fertile sexual partners of subjects must be using two reliable forms of effective contraception during the study unless a study participant/partner is surgically sterile or postmenopausal.
Main Exclusion Criteria:
- Subjects with any history of decompensated liver disease, including but not restricted to portal hypertension as manifested by gastroesophageal varices, variceal bleeding, ascites, or encephalopathy or a hepatic mass lesion suspicious for hepatocellular carcinoma (HCC).
- Liver histology consistent with any other co-existing cause of chronic liver disease (apart from fatty liver).
- Subjects who have been treated for HCV infection within 6 months before Screening.
- Subjects who have been on any experimental protocol or therapy within 28 days before Screening.
- Known HIV infection.
- Chronic hepatitis B infection
- Uncontrolled diabetes.
- Unstable or uncontrolled thyroid disease
- Uncontrolled seizures disorder.
- History of malignant cancer within the last 5 years with the exception of localized basal or squamous cell carcinoma.
- Alcohol and/or drug abuse within the past year.
- Pregnant or lactating women or women who plan to become pregnant during the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00854087
| United States, California | |
| SCTI Research Foundation | |
| Coronado, California, United States, 92118 | |
| VA Palo Alto HCS | |
| Palo Alto, California, United States, 94304 | |
| Huntington Medical Research Institutes | |
| Pasadena, California, United States, 91105 | |
| UC Davis Health System | |
| Sacramento, California, United States, 95817 | |
| Southern California Liver Centers | |
| San Clemente, California, United States, 92673 | |
| United States, Florida | |
| Advanced Medical Research Center | |
| Port Orange, Florida, United States, 32127 | |
| United States, Texas | |
| St. Luke's Advanced Liver Therapies | |
| Houston, Texas, United States, 77030 | |
| United States, Utah | |
| University of Utah HSC | |
| Salt Lake City, Utah, United States, 84132 | |
| Principal Investigator: | Tarek Hassanein, MD | SCTI Research Foundation |
| Responsible Party: | Tarek Hassanein, Medical Director, SCTI Research Foundation |
| ClinicalTrials.gov Identifier: | NCT00854087 |
| Other Study ID Numbers: |
Fuzheng Huayu S-USIIT-01 Study |
| First Posted: | March 2, 2009 Key Record Dates |
| Results First Posted: | June 18, 2014 |
| Last Update Posted: | May 19, 2021 |
| Last Verified: | April 2021 |
|
Hepatitis C Virus HCV Herbal treatment Herbs San Diego Non responder Relapser Treatment failure |
Antifibrotic Anti-fibrotic Fibrosis Failure of previous Interferon based therapy Refuse Interferon based therapy Intolerance to Interferon Male or female 18-70 years of age |
|
Hepatitis A Hepatitis C Hepatitis C, Chronic Hepatitis Hepatitis, Chronic Fibrosis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human |
Virus Diseases Infections Enterovirus Infections Picornaviridae Infections RNA Virus Infections Pathologic Processes Blood-Borne Infections Communicable Diseases Flaviviridae Infections |